MSF urges reform of United States-Mexico-Canada Agreement's (USMCA) pharmaceutical intellectual property provisions to safeguard public health

As part of a public consultation process in advance of the joint review of the United States of America-Mexico-Canada Agreement (USMCA), MSF provided comments outlining how the USMCA in its current form puts the private interests of pharmaceutical corporations above public health. The comments ultimately urged the United States, Mexico, and Canada to pursue a revised USMCA that removes pharmaceutical-related intellectual property provisions in order to help address the shared problem of excessive drug prices and ensure that trade agreements never undermine access to affordable, quality-assured medicines and medical technologies.